284 related articles for article (PubMed ID: 30627867)
21. Exploring Endolysin-Loaded Alginate-Chitosan Nanoparticles as Future Remedy for Staphylococcal Infections.
Kaur J; Kour A; Panda JJ; Harjai K; Chhibber S
AAPS PharmSciTech; 2020 Aug; 21(6):233. PubMed ID: 32794119
[TBL] [Abstract][Full Text] [Related]
22. Chitosan-Coated Alginate Nanoparticles Enhanced Absorption Profile of Insulin Via Oral Administration.
Jaafar MHM; Hamid KA
Curr Drug Deliv; 2019; 16(7):672-686. PubMed ID: 31250754
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
[TBL] [Abstract][Full Text] [Related]
24. Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.
Rajaram S; Vemuri VD; Natham R
J Pharm Biomed Anal; 2014 Nov; 100():103-108. PubMed ID: 25151231
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
[TBL] [Abstract][Full Text] [Related]
26. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
27. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting.
Diab R; Brillault J; Bardy A; Gontijo AV; Olivier JC
Int J Pharm; 2012 Oct; 436(1-2):833-9. PubMed ID: 22846409
[TBL] [Abstract][Full Text] [Related]
28. Inhalable polymer-glycerosomes as safe and effective carriers for rifampicin delivery to the lungs.
Melis V; Manca ML; Bullita E; Tamburini E; Castangia I; Cardia MC; Valenti D; Fadda AM; Peris JE; Manconi M
Colloids Surf B Biointerfaces; 2016 Jul; 143():301-308. PubMed ID: 27022870
[TBL] [Abstract][Full Text] [Related]
29. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Int J Antimicrob Agents; 2005 Oct; 26(4):298-303. PubMed ID: 16154726
[TBL] [Abstract][Full Text] [Related]
30. pH-sensitive chitosan-deoxycholic acid/alginate nanoparticles for oral insulin delivery.
Zhang YW; Tu LL; Tang Z; Wang Q; Zheng GL; Yin LN
Pharm Dev Technol; 2021 Nov; 26(9):943-952. PubMed ID: 34372745
[TBL] [Abstract][Full Text] [Related]
31. Chitosan functionalized poly (ε-caprolactone) nanoparticles for amphotericin B delivery.
Vásquez Marcano RGDJ; Tominaga TT; Khalil NM; Pedroso LS; Mainardes RM
Carbohydr Polym; 2018 Dec; 202():345-354. PubMed ID: 30287009
[TBL] [Abstract][Full Text] [Related]
32. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
33. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation.
Motwani SK; Chopra S; Talegaonkar S; Kohli K; Ahmad FJ; Khar RK
Eur J Pharm Biopharm; 2008 Mar; 68(3):513-25. PubMed ID: 17983737
[TBL] [Abstract][Full Text] [Related]
34. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
[TBL] [Abstract][Full Text] [Related]
35. Response Surface Methodology for Statistical Optimization of Chitosan/Alginate Nanoparticles as a Vehicle for Recombinant Human Bone Morphogenetic Protein-2 Delivery.
Zohri M; Akbari Javar H; Gazori T; Khoshayand MR; Aghaee-Bakhtiari SH; Ghahremani MH
Int J Nanomedicine; 2020; 15():8345-8356. PubMed ID: 33154637
[TBL] [Abstract][Full Text] [Related]
36. Design and evaluation of a novel potential carrier for a hydrophilic antitumor drug: Auricularia auricular polysaccharide-chitosan nanoparticles as a delivery system for doxorubicin hydrochloride.
Xiong W; Li L; Wang Y; Yu Y; Wang S; Gao Y; Liang Y; Zhang G; Pan W; Yang X
Int J Pharm; 2016 Sep; 511(1):267-275. PubMed ID: 27424168
[TBL] [Abstract][Full Text] [Related]
37. Formation and characterization of chitosan-polylacticacid-polyethylene glycol-gelatin nanoparticles: a novel biosystem for controlled drug delivery.
Rajan M; Raj V
Carbohydr Polym; 2013 Oct; 98(1):951-8. PubMed ID: 23987433
[TBL] [Abstract][Full Text] [Related]
38. Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers.
Amarnath Praphakar R; Munusamy MA; Sadasivuni KK; Rajan M
Int J Pharm; 2016 Nov; 513(1-2):628-635. PubMed ID: 27693734
[TBL] [Abstract][Full Text] [Related]
39. Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.
Caetano LA; Almeida AJ; Gonçalves LM
Mar Drugs; 2016 May; 14(5):. PubMed ID: 27187418
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
